hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06311760, orgStudyIdInfo id: D7700C00001, briefTitle: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-09, primaryCompletionDateStruct date: 2024-09-24, completionDateStruct date: 2024-09-24, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: AstraZeneca, class: INDUSTRY, descriptionModule briefSummary: This study will assess the safety, tolerability and pharmacokinetics (PK) of AZD0292 following intravenous (IV) administration of single ascending doses to healthy adult participants., conditionsModule conditions: Healthy Participants Study, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: AZD0292, interventions name: Placebo, outcomesModule primaryOutcomes measure: Number of Participants with Adverse Events, primaryOutcomes measure: Number of Participants with Adverse Events of Special Interest (AESI), secondaryOutcomes measure: Maximum Observed Drug Concentration (Cmax), secondaryOutcomes measure: Area Under Concentration-Curve from Time Zero to the Last Quantifiable Concentration (AUClast), secondaryOutcomes measure: Area Under Concentration-Time Curve from Time Zero to Infinity (AUCinfinity), secondaryOutcomes measure: Number of Participants with Positive Anti-drug Antibodies (ADAs), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Research Site, status: RECRUITING, city: Baltimore, state: Maryland, zip: 21225, country: United States, geoPoint lat: 39.29038, lon: -76.61219, hasResults: False
protocolSection identificationModule nctId: NCT06311747, orgStudyIdInfo id: 24-1T/45, briefTitle: The Effect of Oculomotor Exercises in the Warm-up on Forehand and Backhand Stroke Performance in Tennis Players, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-15, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Ege University, class: OTHER, descriptionModule briefSummary: 30 tennis players aged 12-18, will be included in the study. After their normal warm-up, the participants will make 30 forehand and 30 backhand strokes. Forehand and backhand stroke accuracy rate will be calculated. After a week, additional oculo-motor exercises will be included in the warm-up and the forehand and backhand stroke accuracy rate will be calculated again. The hypothesis that there will be an improvement in forehand and backhand stroke accuracy after oculo-motor exercises will be tested., conditionsModule conditions: Supportive Care, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Oculo-motor exercises, outcomesModule primaryOutcomes measure: Forehand and backhand stroke accuracy, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Ege University Sports Medicine Clinic, status: RECRUITING, city: İzmir, state: Bornova, zip: 35100, country: Turkey, contacts name: Cim CINAR, role: CONTACT, phone: 905375213611, email: cimcinar95@gmail.com, geoPoint lat: 38.41273, lon: 27.13838, hasResults: False
protocolSection identificationModule nctId: NCT06311734, orgStudyIdInfo id: LW231-I-01, briefTitle: A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2021-11-01, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-05-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Shanghai Longwood Biopharmaceuticals Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: To Evaluate the Tolerability and Pharmacokinetics of LW231 Tablets in Single-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Single-dose, Multiple-dose Phase Ia Clinical Trials in Healthy Subjects ., conditionsModule conditions: Chronic Hepatitis B, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: LW231 tablets, interventions name: Placebo, outcomesModule primaryOutcomes measure: Number of Participants With Adverse Events (AEs), secondaryOutcomes measure: Maximum Plasma Concentration (Cmax) of LW231, secondaryOutcomes measure: Time to Cmax (Tmax) of LW231, secondaryOutcomes measure: Area Under the Curve From Time 0 to the Last Measurable Concentration (AUClast) of LW231, secondaryOutcomes measure: Area Under the Curve From Time 0 to 24 Hours (AUC0-24) of LW231, secondaryOutcomes measure: Half-life (t1/2) of LW231, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: The First Hospital of Jilin University, city: Changchun, state: Jilin, country: China, geoPoint lat: 43.88, lon: 125.32278, hasResults: False
protocolSection identificationModule nctId: NCT06311695, orgStudyIdInfo id: IEO 960, briefTitle: Contrast-Enhanced Spectral Mammography (CESM), acronym: CESM, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2012-01-01, primaryCompletionDateStruct date: 2022-02-28, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: The study's objective is to compare the diagnostic accuracy of the contrast-enhanced mammography (CEM), considering as reference the classification obtained with Vacuum Assisted Breast Biopsy (VABB)., conditionsModule conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 325, type: ACTUAL, armsInterventionsModule interventions name: Contrast Enhanced Mammography, outcomesModule primaryOutcomes measure: Evaluation of negative predictive value (NPV) of the CEM, secondaryOutcomes measure: Evaluation of sensitivity of CEM, secondaryOutcomes measure: Evaluation of specificity of CEM, secondaryOutcomes measure: Positive Predictive Value (PPV) of CEM, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, city: Milan, zip: 20141, country: Italy, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06311669, orgStudyIdInfo id: 29409010104798, briefTitle: Comparative Study Between Isolated Iliac Vein Stenting Versus Concomitant Iliac Vein Stenting With Pelvic Vein Embolization in Patients With Pelvic Venous Insufficiency Secondary to Nonthrombotic Iliac Vein Lesions, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: The aim of the study is to compare between Isolated Iliac vein stenting vs Concomitant Iliac vein stenting with pelvic vein embolization in patients with Pelvic Venous Insufficiency secondary to Nonthrombotic iliac vein lesions, conditionsModule conditions: Nonthrombotic Iliac Vein Lesions, conditions: Pelvic Congestive Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: iliac vein stenting, interventions name: pelvic vein embolization, outcomesModule primaryOutcomes measure: Clinical improvement of pain and pelvic symptoms according to the Pelvic Venous Clinical Severity Score (PVCSS), eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ainshams University, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06311656, orgStudyIdInfo id: 18840, secondaryIdInfos id: J5C-MC-FOAA, type: OTHER, domain: DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, briefTitle: A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-12, primaryCompletionDateStruct date: 2024-05-30, completionDateStruct date: 2024-05-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, class: INDUSTRY, collaborators name: Eli Lilly and Company, descriptionModule briefSummary: The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy asian participants and non-Asian participants., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: LY4100511 (DC-853), interventions name: Placebo, outcomesModule primaryOutcomes measure: Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs), secondaryOutcomes measure: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY4100511 (DC-853), secondaryOutcomes measure: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4100511 (DC-853), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Altasciences Clinical Los Angeles, Inc, city: Cypress, state: California, zip: 90630, country: United States, geoPoint lat: 33.81696, lon: -118.03729, hasResults: False
protocolSection identificationModule nctId: NCT06311643, orgStudyIdInfo id: 35, briefTitle: Ameliorative Potential of Relaxing Back Massage on Puerperial Women's Hormones and Infant Weight, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-03-02, primaryCompletionDateStruct date: 2023-09-01, completionDateStruct date: 2024-03-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Kafrelsheikh University, class: OTHER, descriptionModule briefSummary: Effect of massage on hormone levels in puerperal women, conditionsModule conditions: Does Postpartum Massage Affect Leptin, Prolactin and Growth Hormone, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Puerperal woman aged from 25 to 30 years within 4 hours of normal delivery, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: QUADRUPLE, maskingDescription: the assessor and statistician remained blinded throughout the assessment period, unaware of the group assignments., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 45, type: ACTUAL, armsInterventionsModule interventions name: Postpartum back massage in study group, outcomesModule primaryOutcomes measure: Leptin and prolactin levels increase, eligibilityModule sex: FEMALE, minimumAge: 25 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: Kafrelshiekh university, city: Kafrelshiekh, zip: 6850001, country: Egypt, hasResults: False
protocolSection identificationModule nctId: NCT06311630, orgStudyIdInfo id: 65/23/IEC/JMMC&RI, briefTitle: Comparative Study of Analgesic Effect of Ultrasound Guided PENG Block vs FEMORAL BLOCK in Hip Fracture, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-20, primaryCompletionDateStruct date: 2025-01-20, completionDateStruct date: 2025-03-20, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Jubilee Mission Medical College and Research Institute, class: OTHER, descriptionModule briefSummary: To study the analgesic effect of ultrasound guided PENG Block vs Femoral nerve block in patients with Hip fracture presenting to Emergency department, conditionsModule conditions: Hip Fracture, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 70, type: ESTIMATED, outcomesModule primaryOutcomes measure: Comparative Study of Analgesic Effect of Ultrasound Guided PENG Block With FEMORAL NERVE BLOCK in Patients With Hip Fracture as assessed by NRS pain scoring scale by patient, secondaryOutcomes measure: Time taken for each technique, secondaryOutcomes measure: Time taken for adequate analgesia, secondaryOutcomes measure: Incidence of complications, secondaryOutcomes measure: To note if rescue analgesic is required, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Jubilee mission medical College and research centre, status: RECRUITING, city: Thrissur, state: Kerala, zip: 680005, country: India, contacts name: Jogi Varghese, MBBS, role: CONTACT, phone: 9947004222, email: jogi1907@gmail.com, geoPoint lat: 10.51667, lon: 76.21667, hasResults: False
protocolSection identificationModule nctId: NCT06311617, orgStudyIdInfo id: 231592, briefTitle: Retinal Vascular Changes During Pregnancy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2027-01, completionDateStruct date: 2027-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Vanderbilt University Medical Center, class: OTHER, descriptionModule briefSummary: The goal of this study is to better understand how the back part of the eye-called the retina and the choroid-changes during pregnancy. Specialized photos of the eye will be taken at three different timepoints: early in pregnancy (first or second trimester), late in pregnancy (third trimester), and after delivery. This imaging is non-invasive and does not require contact with the surface of the eye. The photos taken will allow assessment of specific parameters, like blood flow and the health of specialized cells that support vision. Understanding how the eyes change during pregnancy may help guide how retina specialists understanding of retinal disease during pregnancy and better inform pregnancy outcomes., conditionsModule conditions: Pregnancy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Fundus photography and optical coherence tomography, outcomesModule primaryOutcomes measure: Imaging Biomarkers: Choroid, primaryOutcomes measure: Imaging Biomarkers: Vessel density, primaryOutcomes measure: Imaging Biomarkers: Foveal avascular zone (FAZ), secondaryOutcomes measure: Fetal Health: delivery, secondaryOutcomes measure: Fetal Health, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Vanderbilt University Medical Center, status: RECRUITING, city: Nashville, state: Tennessee, zip: 37232, country: United States, contacts name: Avni Finn, MD, MBA, role: CONTACT, phone: 615-936-1639, geoPoint lat: 36.16589, lon: -86.78444, hasResults: False
protocolSection identificationModule nctId: NCT06311578, orgStudyIdInfo id: 87704916LUC1001, secondaryIdInfos id: 2023-506495-27-00, type: REGISTRY, domain: EUCT number, briefTitle: A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2028-11-08, completionDateStruct date: 2033-11-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Johnson & Johnson Enterprise Innovation Inc., class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab., conditionsModule conditions: Advanced Solid Tumors, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 66, type: ESTIMATED, armsInterventionsModule interventions name: JNJ-87704916, interventions name: Cetrelimab, outcomesModule primaryOutcomes measure: Part 1: Number of Participants with Dose-Limiting Toxicity (DLT), primaryOutcomes measure: Number of Participants with Adverse Events (AEs) by Severity, secondaryOutcomes measure: Parts 1 and 2: Percentage of Participants With Objective Response (OR), secondaryOutcomes measure: Parts 1 and 2: Percentage of Participants With Disease Control (DC), secondaryOutcomes measure: Parts 1 and 2: Duration of Response (DOR), secondaryOutcomes measure: Part 2: Progression Free Survival (PFS), secondaryOutcomes measure: Part 2: Overall Survival (OS), secondaryOutcomes measure: Parts 1 and 2: Number of JNJ-87704916 Genome Copies per Milliliter, secondaryOutcomes measure: Parts 1 and 2: Payload Concentrations of JNJ-87704916, secondaryOutcomes measure: Parts 1 and 2: Number of Participants with JNJ-87704916 Antibodies, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Center, status: RECRUITING, city: Houston, state: Texas, zip: 77030, country: United States, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06311565, orgStudyIdInfo id: SBU-ISTANBUL-0001, briefTitle: Effects of Education After Colorectal Cancer Screening, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2024-10-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Istanbul Saglik Bilimleri University, class: OTHER, descriptionModule briefSummary: The aim of this study is to examine the effect of the education given to individuals undergoing colorectal cancer screening on their attitudes, beliefs and healthy lifestyle behaviors.This study was planned to be conducted as a prospective randomized controlled study in a family health center in Istanbul. The universe of the research; The sample of individuals registered to the family health center will consist of a total of 70 individuals who meet the inclusion criteria for the study.Patient Diagnosis Form, Colorectal Cancer Screening Attitude Belief Scale, Healthy Lifestyle Behavior Scale II will be used to collect data. Data will be collected at the first encounter, 1 month later, 3 months later, pre-test and post-test. In the research, individuals will be divided into two groups: intervention (n = 35) and control (n = 35). Training will be provided to the intervention group., conditionsModule conditions: Healthy Lifestyle, conditions: Education, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized controlled ( experimental and control group), primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Education, outcomesModule primaryOutcomes measure: Colorectal cancer screening attitude belief scale, primaryOutcomes measure: Healthy lifestyle behaviors scale II, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hilal KARTAL, city: Istanbul, state: Beylikdüzü, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06311552, orgStudyIdInfo id: 0856, briefTitle: Optimising CMR Scan Acquisitions for Novel Equipment/Sequences in Clinical Cardiovascular Populations., acronym: OPTMISE-HFpEF, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-31, primaryCompletionDateStruct date: 2023-11-30, completionDateStruct date: 2023-11-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: University of Leicester, class: OTHER, descriptionModule briefSummary: The purpose of this study is to develop robust protocols for the optimisation of novel hardware, software and exercise equipment in the magnetic resonance imaging (MRI) environment in various cohorts with cardiovascular disease (CVD) with the first study focusing on those with established heart failure with preserved ejection fraction (HFpEF) or those at risk of or with pre-HFpEF., conditionsModule conditions: Heart Failure With Preserved Ejection Fraction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner, outcomesModule primaryOutcomes measure: To develop CMR scanning protocols which acquire the highest quality images during incremental exercise using a stepper ergometer (Ergospect Cardio-stepper)., secondaryOutcomes measure: To determine the reproducibility of the exercise CMR protocols in a test-retest reproducibility sub-study, secondaryOutcomes measure: To determine the optimal scan acquisition protocol for Magnetic Resonance Spectroscopy (MRS) both H+ and 31P using the phosphorous coil in each patient group., secondaryOutcomes measure: To determine the reproducibility of the MRS protocols in a test-retest reproducibility sub-study, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Glenfield Hospital, city: Leicester, country: United Kingdom, geoPoint lat: 52.6386, lon: -1.13169, hasResults: False